Hydrogel microchip as a tool for studying exosomes in human serum
- Authors: Butvilovskaya V.I.1, Tikhonov A.A.1, Savvateeva E.N.1, Ragimov A.A.2, Salimov E.L.2, Voloshin S.A.1, Sidorov D.V.3, Chernichenko M.A.3, Polyakov A.P.3, Filushin M.M.3, Tsybulskaya M.V.1, Rubina A.Y.1
-
Affiliations:
- Engelhardt Institute of Molecular Biology
- Sechenov First Moscow State Medical University
- Herzen Moscow Cancer Research Institute
- Issue: Vol 51, No 5 (2017)
- Pages: 712-717
- Section: Molecular Cell Biology
- URL: https://journal-vniispk.ru/0026-8933/article/view/163239
- DOI: https://doi.org/10.1134/S0026893317050053
- ID: 163239
Cite item
Abstract
Exosomes are cell-derived vesicles that are secreted by both normal and cancer cells. Over the last decade, a few studies have revealed that exosomes cross talk and/or influence major tumor-related pathways such as angiogenesis and metastasis involving many cell types within the tumor microenvironment. The protein composition of the membrane of an exosome reflects that of the membrane of the cell of origin. Because of this, tumor-derived exosomes differ from exosomes that are derived from normal cells. The detection of tumor exosomes and analysis of their molecular composition hold promise for diagnosis and prognosis of cancer. Here, we present hydrogel microarrays (biochips), which contain a panel of immobilized antibodies that recognize tetraspanins (CD9, CD63, CD81) and prognostic markers for colorectal cancer (A33, CD147). These biochips make it possible to analyze the surface proteins of either isolated exosomes or exosomes that are present in the serum samples without isolation. These biochips were successfully used to analyze the surface proteins of exosomes from serum that was collected from a colorectal cancer patient and healthy donor. Biochip-guided immunofluorescent analysis of the exosomes has made it possible for us to detect the A33 antigen and CD147 in the serum sample of the colorectal cancer patient with normal levels of CEA and CA19-9.
Keywords
About the authors
V. I. Butvilovskaya
Engelhardt Institute of Molecular Biology
Author for correspondence.
Email: v.butvilovskaya@gmail.com
Russian Federation, Moscow, 119991
A. A. Tikhonov
Engelhardt Institute of Molecular Biology
Email: v.butvilovskaya@gmail.com
Russian Federation, Moscow, 119991
E. N. Savvateeva
Engelhardt Institute of Molecular Biology
Email: v.butvilovskaya@gmail.com
Russian Federation, Moscow, 119991
A. A. Ragimov
Sechenov First Moscow State Medical University
Email: v.butvilovskaya@gmail.com
Russian Federation, Moscow, 119991
E. L. Salimov
Sechenov First Moscow State Medical University
Email: v.butvilovskaya@gmail.com
Russian Federation, Moscow, 119991
S. A. Voloshin
Engelhardt Institute of Molecular Biology
Email: v.butvilovskaya@gmail.com
Russian Federation, Moscow, 119991
D. V. Sidorov
Herzen Moscow Cancer Research Institute
Email: v.butvilovskaya@gmail.com
Russian Federation, Moscow, 125284
M. A. Chernichenko
Herzen Moscow Cancer Research Institute
Email: v.butvilovskaya@gmail.com
Russian Federation, Moscow, 125284
A. P. Polyakov
Herzen Moscow Cancer Research Institute
Email: v.butvilovskaya@gmail.com
Russian Federation, Moscow, 125284
M. M. Filushin
Herzen Moscow Cancer Research Institute
Email: v.butvilovskaya@gmail.com
Russian Federation, Moscow, 125284
M. V. Tsybulskaya
Engelhardt Institute of Molecular Biology
Email: v.butvilovskaya@gmail.com
Russian Federation, Moscow, 119991
A. Yu. Rubina
Engelhardt Institute of Molecular Biology
Email: v.butvilovskaya@gmail.com
Russian Federation, Moscow, 119991
Supplementary files
